Heat Biologics (HTBX) Reports Promising Interim Phase 2 Lung Cancer Data Investigating HS-110 in Combination with Nivolumab (Opdivo)
​Heat Biologics, Inc. (NASDAQ: HTBX) today announced compelling new interim results from its ongoing Phase 2 study investigating HS-110 in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)